Press Releases

All Releases
View Summary U.S. FDA Grants Priority Review for MM-398 New Drug Application
Jun 25, 2015
PDF 18.7 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to Its Board of Directors
Jun 15, 2015
PDF 110.1 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer
Jun 11, 2015
PDF 16.1 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
Jun 1, 2015
PDF 17.9 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
May 14, 2015
PDF 13.2 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Reports First Quarter 2015 Financial Results
May 7, 2015
PDF 20.7 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer
May 5, 2015
PDF 15.7 KB Add to Briefcase
View Summary Baxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an Investigational Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
May 4, 2015
PDF 14.9 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Timing of First Quarter 2015 Investor Conference Call and Presentation at Credit Suisse 2015 Antibody Conference
Apr 28, 2015
PDF 13.5 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of New Drug Application Submission to U.S. FDA for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
Apr 27, 2015
PDF 16.9 KB Add to Briefcase
View Summary First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients
Apr 21, 2015
PDF 63.6 KB Add to Briefcase
View Summary Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer
Apr 20, 2015
PDF 18.2 KB Add to Briefcase
View Summary Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting
Mar 26, 2015
PDF 14.5 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results
Feb 26, 2015
PDF 26.6 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of MM-121 in Patients with Heregulin Positive Non-Small Cell Lung Cancer
Feb 19, 2015
PDF 20.0 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2014 Investor Conference Call
Feb 12, 2015
PDF 15.1 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Names Birgit M. Schoeberl, Ph.D. as Head of Discovery Division and Announces the Addition of Ulrik B. Nielsen, Ph.D. to Its Board of Directors
Jan 22, 2015
PDF 17.7 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
Jan 20, 2015
PDF 26.8 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
Jan 8, 2015
PDF 17.0 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Jan 7, 2015
PDF 15.2 KB Add to Briefcase
Showing 1-20 of 165 Page: 1 2 3 4 5 ... 9  Next 20
Add to Briefcase = add release to Briefcase

Stock Quote (NASDAQ: MACK)

Price:
10.30

Change:
+ 0.10

Day High:
10.49

Day Low:
10.08

Volume:
640,800

1:03 PM ET on Jul 31, 2015
Delayed ~20 min. By eSignal.

Shareholder Tools